KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ)
$47.08 -0.25 (-0.5282%)
Analysed KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ) News Sources
Kiniksa’s Heart’s Home Campaign Puts ARCALYST Growth Prospects In Focus
09-04-2026
yahoo.com
Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis
08-04-2026
yahoo.com
Stock Of The Day In Buy Zone, Leads Industry Despite Supersmall Market
06-04-2026
yahoo.com
Dow Jones Futures: Leading Stocks Stand Tall As Market Bounces; Look For This Bullish Signal
05-04-2026
yahoo.com
AI-Fueled Trio Leads 5 Stocks To Watch Near Buy Points
04-04-2026
yahoo.com
Exploring High Growth Tech Stocks In The US Market March 2026
27-03-2026
yahoo.com
Tarsus Pharmaceuticals Stock Earns Upgrade To RS Rating
26-03-2026
yahoo.com
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Recent Share Price Pullback
19-03-2026
yahoo.com
Evommune Stock Sees RS Rating Rise To 91
18-03-2026
yahoo.com
KalVista Pharmaceuticals Stock Sees RS Rating Jump To 86
11-03-2026
yahoo.com
What is the current price of KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ)?
The current price of KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ) is $47.08.
KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ) absolute price change since previous trading day?
The absolute price change of KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ) since the previous trading day is $-0.25.
KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ) percentage price change since previous trading day?
The percentage price change of KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ) since the previous trading day is -0.5282%.
What is the most recent average sentiment score for KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ)?
The most recent average sentiment score for KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ) is 78 out of 100.
What is the most recent average sentiment for KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ)?
The most recent sentiment for KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ) is .
SEC-8K** Filing Available For KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.